Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT05695859 Completed - Clinical trials for Breast Cancer Female

99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy

Start date: December 20, 2022
Phase:
Study type: Observational

An open-label, single center study with 99mTc-DARPinG3 SPECT/CT and biopsies of primary tumour and metastatic lymph nodes in breast cancer patients, where the primary endpoint of the study is to find out the correlation between the HER2 expression measured by 99mTc-DARPinG3 SPECT/CT and standard histopathology from relevant tumor and lymph node biopsies.

NCT ID: NCT05693766 Recruiting - Clinical trials for Metastatic Breast Cancer

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

INSIGHT
Start date: September 11, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)

NCT ID: NCT05692674 Recruiting - Breast Cancer Clinical Trials

A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction

Start date: January 10, 2023
Phase: Phase 2
Study type: Interventional

The incidence of breast reconstruction failure after conventional photon radiotherapy for breast cancer is about 18.7%. At present, there is limited data on proton radiotherapy for post operative breast cancer with implantation reconstruction. Proton radiotherapy for breast cancer can significantly reduce the radiation dose of the ipsilateral heart and lung, thereby reducing the incidence of cardiac events and radiation pneumonia. This study is aimed at the study of adjuvant hypofractionated intensity-modulated proton radiotherapy for post operative breast cancer with implantation reconstruction. It can provide an ideal treatment option for such patients to effectively protect the heart and lungs without increasing the failure rate of breast reconstruction after adjuvant radiotherapy.

NCT ID: NCT05692661 Recruiting - Clinical trials for Triple Negative Breast Cancer

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

Start date: January 10, 2023
Phase: Phase 1
Study type: Interventional

Adjuvant radiotherapy is the standard treatment for early breast cancer after breast conserving surgery. Molecular subtypes was significantly associated with the risk of local recurrence of breast cancer. Nguyen et al found that the overall 5-year cumulative incidence of local recurrence was 0.8% for luminal A, 1.5% for luminal B, 8.4% for HER2 positive, and 7.1% for triple negative breast cancer after lumpectomy and radiotherapy. Her2 positive and triple negative breast cancers may be inherently radioresistant. Therefore, for HER2 positive and triple negative breast cancer with high local recurrence and radiation resistance, proton combined with carbon ion is proposed after breast conserving surgery.

NCT ID: NCT05690828 Recruiting - Breast Cancer Clinical Trials

Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer.

e-ONCOGITE
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

This project will investigate the efficacy of a cognitive remediation programme in patients treated for breast cancer. patients will be randomized between "no intervention" and "intervention programme". Efficay will be assessed in term of improved quality of life.

NCT ID: NCT05690295 Completed - Postmenopause Clinical Trials

Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast Cancer

MUSCLE-CLIM
Start date: March 22, 2023
Phase: N/A
Study type: Interventional

Background: In postmenopausal women, an alteration in body composition occurs as a consequence of the secretion of low levels of serum estrogens by the ovaries. Observing an increase in abdominal and mammary fat mass and a decrease in skeletal muscle mass, which is also accompanied by loss of muscle strength and physical function, which leads early to a sarcopenia. On the other hand, the increase in estrogen production by adipose tissue has been associated with an increased risk of breast cancer during menopause because the mammary parenchyma is particularly sensitive to this type of estrogen. For this reason, Hormone Therapy (Aromatase Inhibitors and Tamoxifen) is prescribed in women with estrogen receptor-positive breast cancer. Antineoplastic treatments (Chemotherapy and Hormonal Therapy) have contributed to non-metastatic breast cancer currently presenting a high survival rate, not without adverse effects associated with the course of the disease, age and antineoplastic treatment, affecting various systems, but particularly skeletal muscle mass. Therefore, resistance exercise training has been proposed as an effective intervention strategy to increase muscle mass and strength in different populations. However, the level of muscle response to this type of training in postmenopausal women survivors of breast cancer with and without hormone treatment (Aromatase Inhibitors and Tamoxifen) is unknown.

NCT ID: NCT05689619 Recruiting - Breast Cancer Clinical Trials

SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)

SILMET
Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).

NCT ID: NCT05689398 Recruiting - Breast Cancer Clinical Trials

Rehabilitation on Equal Terms - The ReMig Study

Start date: May 24, 2023
Phase:
Study type: Observational

The ReMig-study aims to increase knowledge about rehabilitation needs, the rehabilitation process of arabic-speaking migrated women with BC, to increase the prerequisites for optimized and equal cancer care. The study aims to map migrated Arabic-speaking women's breast cancer rehabilitation with a focus on mental and physical recovery, lifestyle habits as well as satisfaction and goals with the rehabilitation and compare these outcomes with the outcomes of Swedish-speaking women. Further aim is to explore migrated Arabic-speaking women´s experiences and attitudes towards breast cancer rehabilitation.

NCT ID: NCT05689359 Withdrawn - Breast Cancer Clinical Trials

Evaluation of Hydroxychloroquine to Prevent CIPN

Start date: June 2024
Phase: Phase 2
Study type: Interventional

The study is being done to research if hydroxychloroquine can prevent chemotherapy induced peripheral neuropathy. Certain chemotherapy drugs, like paclitaxel, are known to cause neuropathy which can impact quality of life. Currently, there are no options for preventing peripheral neuropathy. In addition, there are no useful methods to assess peripheral nerve damage. This study will also explore using a study MRI of patients' feet prior to starting chemotherapy and after they have completed chemotherapy to see if there is any difference in their nerve structure.

NCT ID: NCT05689112 Recruiting - Tumor, Brain Clinical Trials

Microscopy Imaging of Whole-mount Stained Human Tissues

Start date: January 10, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this clinical trial is to develop an imaging platform for intraoperative tumor margin delineation in 250 cases of tumor-suffered patients. The main questions it aims to answer are: • to develop the protocol of rapid assessment of surgical specimens without need for fixation, embedding, and cryosectioning required for conventional histopathology. Participants will provide a small piece of their surgical specimens from tumor removal surgery . If there is a comparison group: Researchers will compare normal specimens to see if we can observe the difference.